The first 60 days: HER2-positive breast cancer with brain metastases
The brain is the weak point of HER2-positive breast cancer: antibodies control the rest of the body but cross poorly into the brain, so up to half of patients with advanced disease develop brain metastases. Tucatinib with trastuzumab and capecitabine was the first drug proven to help, and trastuzumab deruxtecan shrinks brain lesions in most patients. Below, week by week, is what OnCo's record of HER2-positive breast cancer with brain metastases says about the first two months: the order is typical, the timing is yours to ask about. Sections appear only where the record has something to say. Orientation, not medical advice.
What happens now
Staging tests establish exactly what and where the cancer is. Everything else follows from the answers.
Ask which of these were tested and what the results were; see the report reader for what each value means.
These specialties appear in the standard of care for this cancer. In most centres they meet weekly as a tumour board to agree each plan; you can ask when yours was discussed and what was decided.
- RadiologistNamed in the standard of care for: Limited brain metastases at first presentation.
- SurgeonNamed in the standard of care for: Limited brain metastases at first presentation.
- Medical oncologistNamed in the standard of care for: Limited brain metastases at first presentation, Active brain metastases after trastuzumab, pertuzumab and trastuzumab emtansine, Brain metastases, stable or active, second line, First-line maintenance to delay brain progression and 1 more.
- Clinical oncologist (radiotherapy)Named in the standard of care for: Limited brain metastases at first presentation.
A second opinion from a centre that treats many similar cases is normal, not rude; the standard of care tells you what to compare it against.
Each row is a setting from the standard of care, in the order it usually arises. Not all will apply to you; your stage and biomarkers decide which do. The guideline grade, where recorded, says how strong the evidence is.
Stereotactic radiosurgery to each lesion, or surgery for a large symptomatic lesion, followed by HER2-directed systemic therapy; whole-brain radiotherapy reserved for many lesions.
Tucatinib with trastuzumab and capecitabine (HER2CLIMB), which improved survival and delayed brain progression.
Trastuzumab deruxtecan, with intracranial responses in most patients (DESTINY-Breast12), positioned as second-line therapy after DESTINY-Breast03.
Neratinib or lapatinib with capecitabine, trastuzumab emtansine with tucatinib (HER2CLIMB-02), repeat radiosurgery, or a clinical trial.
Tucatinib added to trastuzumab and pertuzumab maintenance after induction chemotherapy (HER2CLIMB-05).
Generated from this cancer's standard of care, biomarkers and open problems. Take the group that matches where you are. To tick, add your own and print, open the one-page appointment sheet.
Newly diagnosed
- What is my exact diagnosis, stage, and grade, and which tests established them?Everything else follows from an accurate stage and subtype.
- Which biomarkers have been tested on my tumour (for example HER2 status on the primary or an extracranial metastasis, Contrast-enhanced brain MRI at baseline and every six to twelve weeks on treatment, Number, size and location of lesions, Hormone receptor status, Cerebrospinal fluid cytology when leptomeningeal disease is suspected), and what were the results?These results decide eligibility for targeted therapy, immunotherapy, and trials.
- Which subtype is my cancer, and does that change the recommended treatment?Recognised subtypes for this cancer include Asymptomatic HER2-positive brain metastases found on staging MRI, Active or progressing HER2-positive brain metastases, Stable, previously irradiated HER2-positive brain metastases.
- Is germline (inherited) genetic testing recommended for me or my family?Inherited variants can change treatment and matter for relatives.
Limited brain metastases at first presentation
- For my situation (limited brain metastases at first presentation), which of the standard options do you recommend and why?Guideline options include: Stereotactic radiosurgery to each lesion, or surgery for a large symptomatic lesion, followed by HER2-directed systemic therapy; whole-brain radiotherapy reserved for many lesions.
- How do the results of Alliance N0574 (NCCTG N0574) apply to someone like me?Trial populations differ from individual patients; ask how closely you match.
Active brain metastases after trastuzumab, pertuzumab and trastuzumab emtansine
- For my situation (active brain metastases after trastuzumab, pertuzumab and trastuzumab emtansine), which of the standard options do you recommend and why?Guideline options include: Tucatinib with trastuzumab and capecitabine (HER2CLIMB), which improved survival and delayed brain progression.
- Am I a candidate for Tucatinib, Trastuzumab, Capecitabine, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of HER2CLIMB apply to someone like me?Trial populations differ from individual patients; ask how closely you match.
Brain metastases, stable or active, second line
- For my situation (brain metastases, stable or active, second line), which of the standard options do you recommend and why?Guideline options include: Trastuzumab deruxtecan, with intracranial responses in most patients (DESTINY-Breast12), positioned as second-line therapy after DESTINY-Breast03.
- Am I a candidate for Trastuzumab deruxtecan, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of DESTINY-Breast12 and DESTINY-Breast03 apply to someone like me?Trial populations differ from individual patients; ask how closely you match.
First-line maintenance to delay brain progression
- For my situation (first-line maintenance to delay brain progression), which of the standard options do you recommend and why?Guideline options include: Tucatinib added to trastuzumab and pertuzumab maintenance after induction chemotherapy (HER2CLIMB-05).
- Am I a candidate for Tucatinib, Trastuzumab, Pertuzumab, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of HER2CLIMB-05 apply to someone like me?Trial populations differ from individual patients; ask how closely you match.
Later lines
- For my situation (later lines), which of the standard options do you recommend and why?Guideline options include: Neratinib or lapatinib with capecitabine, trastuzumab emtansine with tucatinib (HER2CLIMB-02), repeat radiosurgery, or a clinical trial.
- Am I a candidate for Neratinib, Lapatinib, Capecitabine or related drugs, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of HER2CLIMB-02 apply to someone like me?Trial populations differ from individual patients; ask how closely you match.
Any stage
- Are there clinical trials I could join, for example of Trastuzumab deruxtecan, Tucatinib, HER2CLIMB-05, Systemic-first management of HER2-positive brain metastases?Trials are how the next standard of care is set; asking early keeps options open.
- Would a second opinion at a high-volume centre change anything, and can you help arrange it?Rare or high-stakes decisions benefit from a centre that treats many similar patients.
- What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?Supportive care improves quality of life and helps patients complete treatment.
- I read that “No randomised trial has compared systemic therapy first with radiosurgery first for asymptomatic lesions”. How does that affect my plan?Open problems are where trials and second opinions matter most.
- I read that “Leptomeningeal disease still has no proven treatment”. How does that affect my plan?Open problems are where trials and second opinions matter most.
Much of what helps in the first weeks is free if you know to ask: testing, helplines, rides and lodging, second opinions, trial travel.
- HER2-positive breast cancer with brain metastases: the full pageThe brain is the weak point of HER2-positive breast cancer: antibodies control the rest of the body but cross poorly into the brain, so up to half of patients with advanced disease develop brain metastases. Tucatinib with trastuzumab and capecitabine was the first drug proven to help, and trastuzumab deruxtecan shrinks brain lesions in most patients.
- One-page appointment sheetYour questions, the words you may hear, what to bring, and space for the answers. Print it.
- Treatment sequencingWhich treatment tends to follow which, line by line.
- NavigatorStandard of care for your stage, what you have tried, and trials near you.
- HER2-positive brain metastases: Up to half of women with metastatic HER2-positive breast cancer develop brain metastases, because antibodies control the body but historically not the brain.
- Leptomeningeal disease: Cancer cells spreading in the fluid and membranes that bathe the brain and spinal cord, rather than as a solid lump.
- Stereotactic radiosurgery (SRS): A single high dose of radiation delivered to a brain tumour or metastasis by beams converging from all sides, so the target gets a destructive dose while the surrounding brain gets little; no scalpel is involved despite the name.
- Brain metastases (intracranial disease): Tumour deposits that have travelled to the brain from a cancer elsewhere, ten times more common than cancers that start in the brain, mostly from lung, breast, melanoma and kidney cancer.
Every term links to the glossary.